Hepatitis C virus broadly neutralizing monoclonal antibodies isolated 25 years after spontaneous clearance

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Merat, Sabrina J ^a   Molenkamp, Richard ^b   Wagner, Koen ^a   Koekkoek, Sylvie M ^b   Van De Berg, Dorien ^a   Yasuda, Etsuko ^a   Böhne, Martino ^a   Claassen, Yvonne B ^a   Grady, Bart P ^c   Prins, Maria ^b,c   Bakker, Arjen Q ^a   De Jong, Menno D ^b   Spits, Hergen ^a   Schinkel, Janke ^b   Beaumont, Tim ^a  

^a AIMM Therapeutics   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD81 ANTIGEN; EPITOPE; EPITOPE II; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C VIRUS BROADLY NEUTRALIZING MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NEUTRALIZING MONOCLONAL ANTIBODY AT12 007; NEUTRALIZING MONOCLONAL ANTIBODY AT12 009; NEUTRALIZING MONOCLONAL ANTIBODY AT12 010; NEUTRALIZING MONOCLONAL ANTIBODY AT12 011; NEUTRALIZING MONOCLONAL ANTIBODY AT13 021; PROTEIN BCL 6; PROTEIN BCL XL; UNCLASSIFIED DRUG; HEPATITIS C ANTIBODY; HEPATITIS VACCINE; VIRUS ENVELOPE PROTEIN;

ADULT; AMINO ACID SEQUENCE; ANTIBODY MEDIATED IMMUNITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CELL IMMORTALIZATION; CONTROLLED STUDY; CROSS REACTION; DRUG DESIGN; DRUG ISOLATION; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; IC50; IMMUNITY; IMMUNOREACTIVITY; INJECTING DRUG USER; MALE; MEMORY CELL; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NONHUMAN; VACCINE PRODUCTION; VIRAL CLEARANCE; B LYMPHOCYTE; BLOOD; CYTOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS C; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; SUBSTANCE ABUSE; VIROLOGY;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; EPITOPES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; SUBSTANCE ABUSE, INTRAVENOUS; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 84992336052     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0165047     Document Type: Article

References (49)

1. Hanafiah Mohd. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013 Feb. 4;57(4):1333-42. doi: 10.1002/hep. 26141 PMID: 23172780
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec. 15;380(9859):2095-128. doi: 10.1016/S0140-6736 (12) 61728-0 PMID: 23245604
3. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013 Jan 3;368(1):34-44. doi: 10. 1056/NEJMoa1208953 PMID: 23281974
4. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014 May 15;370(20):1879-88. doi: 10.1056/NEJMoa1402355 PMID: 24720702
5. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014 May 22;370(21):1973-82. doi: 10.1056/NEJMoa1402869 PMID: 24725237
6. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16;370(3):211-21. doi: 10.1056/NEJMoa1306218 PMID: 24428467
7. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006 Jan; 13(1):34-41. doi: 10.1111/j.1365-2893.2005.00651.x PMID: 16364080
8. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology. 2014 Jan; 59(1):109-20. doi: 10.1002/hep. 26639 PMID: 23908124
9. van den Berg C H BS, Grady BPX, Schinkel J, van de Laar T, Molenkamp R, van Houdt R, et al. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS ONE. 2011;6(11):e27555. doi: 10.1371/journal.pone.0027555 PMID: 22110669
10. Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, et al. Hepatitis C virus reinfection and spontaneous clearance of reinfection-the InC3 Study. J Infect Dis. 2015 Nov. 1;212(9):1407-19. doi: 10.1093/infdis/jiv220 PMID: 25883387
11. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2010 Jan; 138(1):315-24. doi: 10.1053/j.gastro.2009.09.017 PMID: 19782080
12. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000 May 1;191(9):1499-512. PMID: 10790425
13. Schulze zur Wiesch J, Lauer GM, Day CL, Kim AY, Ouchi K, Duncan JE, et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol. 2005 Sep. 15;175(6):3603-13. PMID: 16148104
14. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000 May; 6(5):578-82. doi: 10.1038/75063 PMID: 10802716
15. Pestka JM, Zeisel MB, Bläser E, Schúrmann P, Bartosch B, Cosset F-L, et al. Rapid induction of virusneutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA. 2007 Apr. 3;104(14):6025-30. doi: 10.1073/pnas.0607026104 PMID: 17392433
16. Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, et al. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology. 2014 Jun; 59(6):2140-51. doi: 10.1002/hep. 27013 PMID: 24425349
17. de Jong YP, Dorner M, Mommersteeg MC, Xiao JW, Balazs AB, Robbins JB, et al. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med. 2014 Sep. 17;6(254):254ra129. doi: 10.1126/scitranslmed.3009512 PMID: 25232181
18. Desombere I, Fafi Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, et al. Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. Hepatology. 2016 Apr; 63(4):1120-34. doi: 10.1002/hep. 28428 PMID: 26710081
19. de Taeye SW, Ozorowski G, Torrents de la Peña A, Guttman M, Julien J-P, van den Kerkhof T LGM, et al. Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell. 2015 Dec. 17;163(7):1702-15. doi: 10.1016/j.cell.2015.11.056 PMID: 26687358
20. Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RMB, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. 2015 Sep. 18;349(6254):1301-6. doi: 10.1126/science.aac7263 PMID: 26303961
21. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GBE, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013 Nov. 1;342(6158):592-8. doi: 10.1126/science.1243283 PMID: 24179220
22. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science. 2013 Nov. 29;342(6162):1090-4. doi: 10.1126/science.1243876 PMID: 24288331
23. Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV, Cygan A, et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature. 2014 May 15;509(7500):381-4. doi: 10.1038/nature13117 PMID: 24553139
24. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset F-L, et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol. 2005 Sep; 79(17):11095-104. doi: 10.1128/JVI.79.17.11095-11104.2005 PMID: 16103160
25. Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu M-YW, Alter HJ, et al. Hepatitis C virus epitopespecific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA. 2007 May 15;104(20):8449-54. doi: 10.1073/pnas.0703039104 PMID: 17494735
26. Keck Z-Y, Op De Beeck A, Hadlock KG, Xia J, Li T-K, Dubuisson J, et al. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol. 2004 Sep; 78(17):9224-32. doi: 10.1128/JVI.78.17.9224-9232.2004 PMID: 15308717
27. Owsianka AM, Tarr AW, Keck ZY, Li TK, Witteveldt J, Adair R, et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol. 2008 Mar. 1;89(3):653-9.
28. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med. 2008 Jan; 14(1):25-7. doi: 10.1038/nm1698 PMID: 18064037
29. Meunier J-C, Russell RS, Goossens V, Priem S, Walter H, Depla E, et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol. 2008 Jan; 82(2):966-73. doi: 10.1128/JVI.01872-07 PMID: 17977972
30. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci USA. 2012 Apr. 17;109(16):6205-10. doi: 10.1073/pnas.1114927109 PMID: 22492964
31. van den Hoek JA, Coutinho RA, van Haastrecht HJ, van Zadelhoff AW, Goudsmit J. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS. 1988 Feb; 2(1):55-60. PMID: 3128998
32. van den Berg C H SB, Smit C, Bakker M, Geskus RB, Berkhout B, Jurriaans S, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol. 2007;22(3):183-93. doi: 10.1007/s10654-006-9089-7 PMID: 17334821
33. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CMM, Lukens MV, et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med. 2010 Jan; 16(1):123-8. doi: 10.1038/nm.2071 PMID: 20023635
34. Albecka A, Montserret R, Krey T, Tarr AW, Diesis E, Ball JK, et al. Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. J Virol. 2011 Jan 20;85(4):1777-92. doi: 10. 1128/JVI.02170-10 PMID: 21147916
35. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, et al. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology. 2005 Feb; 41(2):265-74. doi: 10.1002/hep. 20542 PMID: 15660396
36. Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuisson J, et al. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci USA. 2007 Oct. 9;104(41):16269-74. doi: 10.1073/pnas.0705522104 PMID: 17911260
37. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol. 1990 Mar; 28(3):495-503. PMID: 1691208
38. Wagner K, Kwakkenbos MJ, Claassen YB, Maijoor K, Bóhne M, van der Sluijs KF, et al. Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity. Proc Natl Acad Sci USA. 2014 Nov. 25;111(47):16820-5. doi: 10.1073/pnas.1408605111 PMID: 25385586
39. Cocquerel L, Meunier JC, Pillez A, Wychowski C, Dubuisson J. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol. 1998 Mar; 72(3):2183-91. PMID: 9499075
40. Op De Beeck A, Voisset C, Bartosch B, Ciczora Y, Cocquerel L, Keck Z, et al. Characterization of functional hepatitis C virus envelope glycoproteins. J Virol. 2004 Mar; 78(6):2994-3002. doi: 10.1128/JVI. 78.6.2994-3002.2004 PMID: 14990718
41. Keck Z-Y, Xia J, Wang Y, Wang W, Krey T, Prentoe J, et al. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog. 2012;8(4):e1002653. doi: 10.1371/journal.ppat.1002653 PMID: 22511875
42. Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJP, Hickling TP, et al. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology. 2006 Mar; 43(3):592-601. doi: 10.1002/hep. 21088 PMID: 16496330
43. van den Berg C HSB, van de Laar TJW, Kok A, Zuure FR, Coutinho RA, Prins M. Never injected, but hepatitis C virus-infected: a study among self-declared never-injecting drug users from the Amsterdam Cohort Studies. J Viral Hepat. 2009 Aug; 16(8):568-77. doi: 10.1111/j.1365-2893.2009.01105.x PMID: 19243497
44. van de Laar TJW, Molenkamp R, van den Berg C, Schinkel J, Beld M G HM, Prins M, et al. Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam. J Hepat. 2009 Oct; 51(4):667-74.
45. Urbanowicz RA, McClure CP, Brown RJP, Tsoleridis T, Persson MAA, Krey T, et al. A diverse panel of Hepatitis C Virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance. J Virol. 2015 Dec. 23;: JVI.02700-15.
46. Keck Z, Wang W, Wang Y, Lau P, Carlsen THR, Prentoe J, et al. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol. 2013 Jan; 87(1):37-51. doi: 10.1128/JVI.01941-12 PMID: 23097455
47. Perotti M, Mancini N, Diotti RA, Tarr AW, Ball JK, Owsianka A, et al. Identification of a broadly crossreacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol. 2008 Jan; 82(2):1047-52. doi: 10.1128/JVI.01986-07 PMID: 17989176
48. Carlsen THR, Pedersen J, Prentoe JC, Giang E, Keck Z-Y, Mikkelsen LS, et al. Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology. 2014 Nov; 60(5):1551-62. doi: 10.1002/hep. 27298 PMID: 25043937
49. Swann RE, Cowton VM, Robinson MW, Cole SJ, Barclay ST, Mills PR, et al. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection. J Virol. 2016 May 1;90(9):4530-43. doi: 10.1128/JVI.02669-15 PMID: 26912610